Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acewyn-MR is an oral combination tablet developed by Garwyn Remedies for the management of acute, painful musculoskeletal conditions and associated muscle spasms. It contains three active ingredients: the non-steroidal anti-inflammatory drug (NSAID) aceclofenac, the analgesic and antipyretic paracetamol (acetaminophen), and the centrally acting skeletal muscle relaxant chlorzoxazone. Aceclofenac and paracetamol work synergistically to alleviate pain and reduce inflammation by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby suppressing prostaglandin synthesis. Chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs responsible for muscle spasms, a mechanism mediated in part by the activation of small- and intermediate-conductance calcium-activated potassium channels (KCa2.2 and KCa3.1). Together, these components provide comprehensive relief from pain, stiffness, and muscle tension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acewyn-MR.